JP4614473B2 - 新規なｉｆｎ受容体１結合タンパク質、それらをコードするｄｎａ、およびインターフェロンに対する細胞応答の調節方法 - Google Patents

新規なｉｆｎ受容体１結合タンパク質、それらをコードするｄｎａ、およびインターフェロンに対する細胞応答の調節方法 Download PDF

Info

Publication number: JP4614473B2
Authority: JP; Japan
Prior art keywords: sequence; seq; dna molecule; protein; ifnar1
Prior art date: 1997-01-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP53237098A

Other languages

English (en)

Japanese (ja)

Other versions

JP2001508306A (ja

JP2001508306A5 (et

Inventor

レベル、マイクル

アブラモビッチ、カロライナ

イーチェバス、ジュディス

Original Assignee

イエダリサーチアンドディベロップメントカンパニーリミテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-15

Filing date

1998-01-15

Publication date

2011-01-19

1998-01-15 Application filed by イエダリサーチアンドディベロップメントカンパニーリミテッド filed Critical イエダリサーチアンドディベロップメントカンパニーリミテッド

2001-06-26 Publication of JP2001508306A publication Critical patent/JP2001508306A/ja

2005-08-11 Publication of JP2001508306A5 publication Critical patent/JP2001508306A5/ja

2011-01-19 Application granted granted Critical

2011-01-19 Publication of JP4614473B2 publication Critical patent/JP4614473B2/ja

2018-01-15 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

102000014150 Interferons Human genes 0.000 title claims description 72
108010050904 Interferons Proteins 0.000 title claims description 72
229940079322 interferon Drugs 0.000 title claims description 71
238000000034 method Methods 0.000 title claims description 21
230000036755 cellular response Effects 0.000 title abstract description 13
102000052510 DNA-Binding Proteins Human genes 0.000 title description 4
108700020911 DNA-Binding Proteins Proteins 0.000 title description 4
108090000623 proteins and genes Proteins 0.000 claims abstract description 73
102000004169 proteins and genes Human genes 0.000 claims abstract description 62
230000000692 anti-sense effect Effects 0.000 claims abstract description 37
101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 claims abstract description 10
102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 claims abstract description 9
210000004027 cell Anatomy 0.000 claims description 69
102000053602 DNA Human genes 0.000 claims description 29
108020004511 Recombinant DNA Proteins 0.000 claims description 28
108020004999 messenger RNA Proteins 0.000 claims description 25
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 22
239000012634 fragment Substances 0.000 claims description 19
230000014509 gene expression Effects 0.000 claims description 19
239000002773 nucleotide Substances 0.000 claims description 19
125000003729 nucleotide group Chemical group 0.000 claims description 19
108020004414 DNA Proteins 0.000 claims description 17
210000005260 human cell Anatomy 0.000 claims description 13
108090000467 Interferon-beta Proteins 0.000 claims description 12
102100026720 Interferon beta Human genes 0.000 claims description 11
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
239000013604 expression vector Substances 0.000 claims description 8
101710146873 Receptor-binding protein Proteins 0.000 claims description 7
102000006992 Interferon-alpha Human genes 0.000 claims description 6
108010047761 Interferon-alpha Proteins 0.000 claims description 6
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 6
230000004083 survival effect Effects 0.000 claims description 6
230000036961 partial effect Effects 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 1
238000012258 culturing Methods 0.000 claims 1
230000001939 inductive effect Effects 0.000 claims 1
102100022985 Protein arginine N-methyltransferase 1 Human genes 0.000 abstract description 102
101100216108 Homo sapiens PRMT1 gene Proteins 0.000 abstract description 93
238000002955 isolation Methods 0.000 abstract 1
239000002299 complementary DNA Substances 0.000 description 43
150000001413 amino acids Chemical group 0.000 description 34
230000000694 effects Effects 0.000 description 33
102000005962 receptors Human genes 0.000 description 25
108020003175 receptors Proteins 0.000 description 25
239000011324 bead Substances 0.000 description 19
239000013612 plasmid Substances 0.000 description 19
240000004808 Saccharomyces cerevisiae Species 0.000 description 18
108090000765 processed proteins & peptides Proteins 0.000 description 16
230000027455 binding Effects 0.000 description 15
108010042955 Calcineurin Proteins 0.000 description 14
102000004631 Calcineurin Human genes 0.000 description 14
108091034117 Oligonucleotide Proteins 0.000 description 14
239000013598 vector Substances 0.000 description 14
238000000338 in vitro Methods 0.000 description 13
102000004190 Enzymes Human genes 0.000 description 12
108090000790 Enzymes Proteins 0.000 description 12
229940088598 enzyme Drugs 0.000 description 12
210000001519 tissue Anatomy 0.000 description 12
108010068032 caltractin Proteins 0.000 description 11
238000013519 translation Methods 0.000 description 11
108020005544 Antisense RNA Proteins 0.000 description 9
101000757216 Homo sapiens Protein arginine N-methyltransferase 1 Proteins 0.000 description 9
206010035226 Plasma cell myeloma Diseases 0.000 description 9
239000000427 antigen Substances 0.000 description 9
108091007433 antigens Proteins 0.000 description 9
102000036639 antigens Human genes 0.000 description 9
239000000074 antisense oligonucleotide Substances 0.000 description 9
238000012230 antisense oligonucleotides Methods 0.000 description 9
239000003184 complementary RNA Substances 0.000 description 9
239000000284 extract Substances 0.000 description 9
201000000050 myeloid neoplasm Diseases 0.000 description 9
239000000047 product Substances 0.000 description 9
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
108010001515 Galectin 4 Proteins 0.000 description 8
102100039556 Galectin-4 Human genes 0.000 description 8
206010028980 Neoplasm Diseases 0.000 description 8
102000003708 Protein arginine N-methyltransferase Human genes 0.000 description 8
230000009471 action Effects 0.000 description 8
229920001184 polypeptide Polymers 0.000 description 8
102000004196 processed proteins & peptides Human genes 0.000 description 8
230000004044 response Effects 0.000 description 8
238000010396 two-hybrid screening Methods 0.000 description 8
102100026189 Beta-galactosidase Human genes 0.000 description 7
108010045403 Calcium-Binding Proteins Proteins 0.000 description 7
102000005701 Calcium-Binding Proteins Human genes 0.000 description 7
108010070675 Glutathione transferase Proteins 0.000 description 7
102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 7
108010033040 Histones Proteins 0.000 description 7
108020000912 Protein arginine N-methyltransferase Proteins 0.000 description 7
108010005774 beta-Galactosidase Proteins 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
230000003993 interaction Effects 0.000 description 7
150000007523 nucleic acids Chemical group 0.000 description 7
102000014914 Carrier Proteins Human genes 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
108090000144 Human Proteins Proteins 0.000 description 6
102000003839 Human Proteins Human genes 0.000 description 6
108091081021 Sense strand Proteins 0.000 description 6
108091008324 binding proteins Proteins 0.000 description 6
230000000295 complement effect Effects 0.000 description 6
108020001507 fusion proteins Proteins 0.000 description 6
102000037865 fusion proteins Human genes 0.000 description 6
102000039446 nucleic acids Human genes 0.000 description 6
108020004707 nucleic acids Proteins 0.000 description 6
210000000056 organ Anatomy 0.000 description 6
238000012163 sequencing technique Methods 0.000 description 6
108020000948 Antisense Oligonucleotides Proteins 0.000 description 5
241000701044 Human gammaherpesvirus 4 Species 0.000 description 5
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
108091081024 Start codon Proteins 0.000 description 5
108091023040 Transcription factor Proteins 0.000 description 5
102000040945 Transcription factor Human genes 0.000 description 5
230000002950 deficient Effects 0.000 description 5
230000006870 function Effects 0.000 description 5
230000012010 growth Effects 0.000 description 5
239000000758 substrate Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
102100023344 Centromere protein F Human genes 0.000 description 4
101001032016 Clostridium acetobutylicum (strain ATCC 824 / DSM 792 / JCM 1419 / LMG 5710 / VKM B-1787) Hydroxylamine reductase 1 Proteins 0.000 description 4
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
102000016397 Methyltransferase Human genes 0.000 description 4
108060004795 Methyltransferase Proteins 0.000 description 4
230000004913 activation Effects 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000033228 biological regulation Effects 0.000 description 4
230000004927 fusion Effects 0.000 description 4
238000011081 inoculation Methods 0.000 description 4
239000006166 lysate Substances 0.000 description 4
229960004452 methionine Drugs 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
210000001995 reticulocyte Anatomy 0.000 description 4
239000007261 sc medium Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
241000701161 unidentified adenovirus Species 0.000 description 4
210000005253 yeast cell Anatomy 0.000 description 4
102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
108020004463 18S ribosomal RNA Proteins 0.000 description 3
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
229920000936 Agarose Polymers 0.000 description 3
101000999354 Bos taurus Interferon alpha-H Proteins 0.000 description 3
208000003174 Brain Neoplasms Diseases 0.000 description 3
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
230000004568 DNA-binding Effects 0.000 description 3
101100149416 Drosophila melanogaster shakB gene Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
102000006947 Histones Human genes 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
102000002227 Interferon Type I Human genes 0.000 description 3
108010014726 Interferon Type I Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
101100216112 Rattus norvegicus Prmt1 gene Proteins 0.000 description 3
108700008625 Reporter Genes Proteins 0.000 description 3
101100296423 Streptococcus intermedius pas gene Proteins 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229910001424 calcium ion Inorganic materials 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
210000000805 cytoplasm Anatomy 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
239000003599 detergent Substances 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000009036 growth inhibition Effects 0.000 description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
230000006698 induction Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
210000004940 nucleus Anatomy 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
101800001415 Bri23 peptide Proteins 0.000 description 2
102400000107 C-terminal peptide Human genes 0.000 description 2
101800000655 C-terminal peptide Proteins 0.000 description 2
AMEWKZJIYHFYGL-PIBDHAAFSA-N CN[C@@H](CC[S+](C)C[C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC=NC(N)=C2N=C1)C([O-])=O Chemical compound CN[C@@H](CC[S+](C)C[C@H]([C@H]([C@H]1O)O)O[C@H]1N1C2=NC=NC(N)=C2N=C1)C([O-])=O AMEWKZJIYHFYGL-PIBDHAAFSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
102000016675 EF-hand domains Human genes 0.000 description 2
108050006297 EF-hand domains Proteins 0.000 description 2
241001131785 Escherichia coli HB101 Species 0.000 description 2
101150094690 GAL1 gene Proteins 0.000 description 2
102100028501 Galanin peptides Human genes 0.000 description 2
101100121078 Homo sapiens GAL gene Proteins 0.000 description 2
230000004163 JAK-STAT signaling pathway Effects 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
102000055027 Protein Methyltransferases Human genes 0.000 description 2
108700040121 Protein Methyltransferases Proteins 0.000 description 2
102000044126 RNA-Binding Proteins Human genes 0.000 description 2
108700020471 RNA-Binding Proteins Proteins 0.000 description 2
102000004389 Ribonucleoproteins Human genes 0.000 description 2
108010081734 Ribonucleoproteins Proteins 0.000 description 2
101150099493 STAT3 gene Proteins 0.000 description 2
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
101710120037 Toxin CcdB Proteins 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
230000003302 anti-idiotype Effects 0.000 description 2
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
239000011575 calcium Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
239000000499 gel Substances 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
230000009422 growth inhibiting effect Effects 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000012482 interaction analysis Methods 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
235000021109 kimchi Nutrition 0.000 description 2
101150066555 lacZ gene Proteins 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000011987 methylation Effects 0.000 description 2
238000007069 methylation reaction Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000037361 pathway Effects 0.000 description 2
229950000964 pepstatin Drugs 0.000 description 2
108010091212 pepstatin Proteins 0.000 description 2
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
108010013516 peptide R1 Proteins 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
230000001124 posttranscriptional effect Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
241000894007 species Species 0.000 description 2
238000010186 staining Methods 0.000 description 2
230000008685 targeting Effects 0.000 description 2
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
101710091601 21 kDa protein Proteins 0.000 description 1
101710176159 32 kDa protein Proteins 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
108020004491 Antisense DNA Proteins 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
101100329226 Bacillus anthracis cpfC1 gene Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
OWPWFVVPBYFKBG-SXDHXEJRSA-N Calactin Chemical compound C1([C@@H]2[C@@]3(C)CC[C@H]4[C@H]([C@]3(CC2)O)CC[C@@H]2[C@]4(C=O)C[C@H]3O[C@@]4(O)[C@H](O)C[C@H](O[C@H]4O[C@@H]3C2)C)=CC(=O)OC1 OWPWFVVPBYFKBG-SXDHXEJRSA-N 0.000 description 1
OBQNBKMFLGEKOP-UHFFFAOYSA-N Calactin Natural products CC1CC(O)C2(O)OC3CC4CCC5C(CCC6(C)C(CCC56O)C7=CC(=O)OC7)C4(CC3OC2O1)C=O OBQNBKMFLGEKOP-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
101710117451 Calmodulin-like protein Proteins 0.000 description 1
GOWXBEGTCITRER-UHFFFAOYSA-N Calotropin Natural products CC1CC(O)C(=O)C(OC2CCC3(C=O)C(CCC4C3CC(O)C5(C)C(CCC45O)C6=CC(=O)OC6)C2)O1 GOWXBEGTCITRER-UHFFFAOYSA-N 0.000 description 1
108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102100030013 Endoribonuclease Human genes 0.000 description 1
101710199605 Endoribonuclease Proteins 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
101150031823 HSP70 gene Proteins 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
108010054267 Interferon Receptors Proteins 0.000 description 1
102000001617 Interferon Receptors Human genes 0.000 description 1
108010086140 Interferon alpha-beta Receptor Proteins 0.000 description 1
102000007438 Interferon alpha-beta Receptor Human genes 0.000 description 1
102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
102000015617 Janus Kinases Human genes 0.000 description 1
108010024121 Janus Kinases Proteins 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
102000006835 Lamins Human genes 0.000 description 1
108010047294 Lamins Proteins 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
102000043129 MHC class I family Human genes 0.000 description 1
108091054437 MHC class I family Proteins 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
108700019961 Neoplasm Genes Proteins 0.000 description 1
102000048850 Neoplasm Genes Human genes 0.000 description 1
101100285000 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-3 gene Proteins 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
101000912093 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Cell division control protein 24 Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
101150006914 TRP1 gene Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 1
241000700605 Viruses Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
229960001570 ademetionine Drugs 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000003816 antisense DNA Substances 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
244000309466 calf Species 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
101150073031 cdk2 gene Proteins 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
210000003793 centrosome Anatomy 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
230000021572 chromosome movement towards spindle pole Effects 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000004590 computer program Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
102000003675 cytokine receptors Human genes 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000003436 cytoskeletal effect Effects 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000011981 development test Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
150000001982 diacylglycerols Chemical class 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
101150052825 dnaK gene Proteins 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000459 effect on growth Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000009088 enzymatic function Effects 0.000 description 1
238000003348 filter assay Methods 0.000 description 1
230000004907 flux Effects 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
108010083391 glycinin Proteins 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
102000054261 human IFNAR1 Human genes 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
229960001388 interferon-beta Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000002372 labelling Methods 0.000 description 1
210000005053 lamin Anatomy 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
108091005592 methylated proteins Proteins 0.000 description 1
230000001035 methylating effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000008520 organization Effects 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
210000004896 polypeptide structure Anatomy 0.000 description 1
230000007859 posttranscriptional regulation of gene expression Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000037452 priming Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
238000001814 protein method Methods 0.000 description 1
230000019639 protein methylation Effects 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000007727 signaling mechanism Effects 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000010257 thawing Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
102000027257 transmembrane receptors Human genes 0.000 description 1
108091008578 transmembrane receptors Proteins 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Transplantation (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP53237098A 1997-01-15 1998-01-15 新規なｉｆｎ受容体１結合タンパク質、それらをコードするｄｎａ、およびインターフェロンに対する細胞応答の調節方法 Expired - Fee Related JP4614473B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US3563697P	1997-01-15	1997-01-15
US60/035,636		1997-01-15
PCT/US1998/000671 WO1998031796A1 (en)	1997-01-15	1998-01-15	Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons

Publications (3)

Publication Number	Publication Date
JP2001508306A JP2001508306A (ja)	2001-06-26
JP2001508306A5 JP2001508306A5 (et)	2005-08-11
JP4614473B2 true JP4614473B2 (ja)	2011-01-19

Family

ID=21883894

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP53237098A Expired - Fee Related JP4614473B2 (ja)	1997-01-15	1998-01-15	新規なｉｆｎ受容体１結合タンパク質、それらをコードするｄｎａ、およびインターフェロンに対する細胞応答の調節方法

Country Status (20)

Country	Link
US (1)	US7264945B2 (et)
EP (1)	EP1019500B1 (et)
JP (1)	JP4614473B2 (et)
KR (2)	KR100591988B1 (et)
CN (1)	CN1212398C (et)
AT (1)	ATE342972T1 (et)
AU (1)	AU731206C (et)
BG (1)	BG64829B1 (et)
BR (1)	BR9806755A (et)
CA (1)	CA2276111A1 (et)
CZ (1)	CZ299096B6 (et)
DE (1)	DE69836226T2 (et)
DK (1)	DK1019500T3 (et)
EA (1)	EA003250B1 (et)
EE (1)	EE04819B1 (et)
ES (1)	ES2275297T3 (et)
IL (2)	IL130960A0 (et)
NO (1)	NO326104B1 (et)
UA (1)	UA75560C2 (et)
WO (1)	WO1998031796A1 (et)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020119129A1 (en) *	1997-01-15	2002-08-29	Yeda Research And Development Co. Ltd.	Novel IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons
WO2003055506A1 (fr) *	2001-12-27	2003-07-10	Takeda Chemical Industries, Ltd.	Medicaments pour la prevention et le traitement du cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4220759A1 (de) *	1992-06-24	1994-01-05	Inst Genbiologische Forschung	DNA-Sequenzen für Oligosaccharid-Transporter, Plasmide, Bakterien und Pflanzen enthaltend einen Transporter sowie Verfahren zur Herstellung und Transformation von Hefestämmen zur Identifikation des Transporteers
IL107378A (en) *	1993-10-24	2005-05-17	Yeda Res & Dev	SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE
US6242587B1 (en) *	1996-10-02	2001-06-05	The University Of North Carolina At Chapel Hill	DNA molecules encoding a calcium-integrin binding protein

1998
- 1998-01-15 JP JP53237098A patent/JP4614473B2/ja not_active Expired - Fee Related
- 1998-01-15 AT AT98901804T patent/ATE342972T1/de active
- 1998-01-15 DE DE69836226T patent/DE69836226T2/de not_active Expired - Lifetime
- 1998-01-15 CZ CZ0247199A patent/CZ299096B6/cs not_active IP Right Cessation
- 1998-01-15 IL IL13096098A patent/IL130960A0/xx active IP Right Grant
- 1998-01-15 EE EEP199900272A patent/EE04819B1/et unknown
- 1998-01-15 KR KR1020057004384A patent/KR100591988B1/ko not_active IP Right Cessation
- 1998-01-15 BR BR9806755-9A patent/BR9806755A/pt not_active Application Discontinuation
- 1998-01-15 AU AU58240/98A patent/AU731206C/en not_active Ceased
- 1998-01-15 KR KR1019997006407A patent/KR100799828B1/ko not_active IP Right Cessation
- 1998-01-15 CA CA002276111A patent/CA2276111A1/en not_active Abandoned
- 1998-01-15 WO PCT/US1998/000671 patent/WO1998031796A1/en not_active Application Discontinuation
- 1998-01-15 DK DK98901804T patent/DK1019500T3/da active
- 1998-01-15 EA EA199900663A patent/EA003250B1/ru not_active IP Right Cessation
- 1998-01-15 ES ES98901804T patent/ES2275297T3/es not_active Expired - Lifetime
- 1998-01-15 CN CNB98801808XA patent/CN1212398C/zh not_active Expired - Fee Related
- 1998-01-15 UA UA99084631A patent/UA75560C2/uk unknown
- 1998-01-15 EP EP98901804A patent/EP1019500B1/en not_active Expired - Lifetime
1999
- 1999-07-09 NO NO19993412A patent/NO326104B1/no not_active IP Right Cessation
- 1999-07-14 IL IL130960A patent/IL130960A/en not_active IP Right Cessation
- 1999-08-02 BG BG103627A patent/BG64829B1/bg unknown
2002
- 2002-12-04 US US10/309,280 patent/US7264945B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EA199900663A1 (ru)	2000-02-28
AU731206B2 (en)	2001-03-29
CZ247199A3 (cs)	2000-01-12
EP1019500B1 (en)	2006-10-18
EE04819B1 (et)	2007-04-16
AU5824098A (en)	1998-08-07
IL130960A (en)	2008-03-20
KR20000070181A (ko)	2000-11-25
CN1243544A (zh)	2000-02-02
CA2276111A1 (en)	1998-07-23
EP1019500A4 (en)	2004-04-07
EE9900272A (et)	2000-02-15
US7264945B2 (en)	2007-09-04
BG64829B1 (bg)	2006-05-31
CN1212398C (zh)	2005-07-27
EA003250B1 (ru)	2003-02-27
ATE342972T1 (de)	2006-11-15
KR100591988B1 (ko)	2006-06-21
ES2275297T3 (es)	2007-06-01
AU731206C (en)	2002-05-16
KR100799828B1 (ko)	2008-01-31
KR20050046779A (ko)	2005-05-18
WO1998031796A8 (en)	1999-05-20
NO993412D0 (no)	1999-07-09
CZ299096B6 (cs)	2008-04-23
DK1019500T3 (da)	2007-02-19
WO1998031796A1 (en)	1998-07-23
DE69836226T2 (de)	2007-02-01
JP2001508306A (ja)	2001-06-26
EP1019500A2 (en)	2000-07-19
UA75560C2 (en)	2006-05-15
NO326104B1 (no)	2008-09-22
DE69836226D1 (de)	2006-11-30
IL130960A0 (en)	2001-01-28
BG103627A (en)	2000-04-28
US20030176678A1 (en)	2003-09-18
NO993412L (no)	1999-07-09
BR9806755A (pt)	2000-03-14

Publication	Publication Date	Title
Donalies et al.	1991	Expression of M-cadherin, a member of the cadherin multigene family, correlates with differentiation of skeletal muscle cells.
KR100687388B1 (ko)	2007-02-26	인터루킨-18 결합 단백질, 이들의 제조방법 및 용도
AU743490B2 (en)	2002-01-24	NTN-2 member of TNF ligand family
KR100439290B1 (ko)	2004-09-13	인터로이칸-18을인식하는신규의폴리펩티드
US7696150B2 (en)	2010-04-13	Modulation of the activity of an interleukin 17 receptor-related protein, EVI27, and uses thereof
HU226328B1 (en)	2008-09-29	Modulators of tnf receptor associated factor (traf), their preparation and use
JP4614473B2 (ja)	2011-01-19	新規なｉｆｎ受容体１結合タンパク質、それらをコードするｄｎａ、およびインターフェロンに対する細胞応答の調節方法
US7524928B2 (en)	2009-04-28	IFN receptor 1 binding proteins
US5650313A (en)	1997-07-22	Ubiquitin conjugating enzymes 8 and 9
JP3231262B2 (ja)	2001-11-19	ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体
AU6176696A (en)	1997-01-22	Interleukin-1 receptor-associated protein kinase and assays
EP1780277A1 (en)	2007-05-02	IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons
KR19980703889A (ko)	1998-12-05	임파구 인터페론 조절 인자 폴리펩티드를 코딩하는 유전자
EP0837936B1 (en)	2006-11-29	New immunoregulatory protein lst-1
MXPA99006595A (en)	2000-01-21	Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons
KR100808925B1 (ko)	2008-03-03	돼지 ｌａｇ-3 융합 이뮤노글로블린
PT1019500E (pt)	2007-01-31	Proteinas de ligação ao novo receptor do ifn 1, dna que as codifica e metodos de modulação da resposta celular à interferões
WO2000056158A1 (en)	2000-09-28	Composition and methods for the treatment of cancer and viral infections

Legal Events

Date	Code	Title	Description
2004-12-24	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041202
2004-12-24	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041202
2008-01-22	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080122
2008-05-22	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080422
2008-06-09	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080609
2008-06-12	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080522
2008-06-30	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080630
2008-07-10	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080620
2009-03-31	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090331
2009-07-23	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090630
2009-07-23	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090629
2009-08-10	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090810
2010-03-16	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100316
2010-07-08	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100615
2010-07-08	RD03	Notification of appointment of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20100615
2010-07-26	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100726
2010-07-29	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100709
2010-09-13	TRDD	Decision of grant or rejection written
2010-09-21	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100921
2010-09-24	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2010-10-28	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101019
2010-10-29	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2010-11-01	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20131029 Year of fee payment: 3
2013-10-08	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2014-10-07	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2015-10-06	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-10-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2017-10-29	LAPS	Cancellation because of no payment of annual fees